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Molecular markers involved in DNA repair can help to predict survival in gastric cancer patients treated with 5-FU plus platinum
chemotherapy. Excision repair cross-complementing 1 (ERCC1) and thymidylate synthase (TS) mRNA expression levels were
assessed in advanced gastric cancer tumour samples using real-time quantitative PCR in 76 patients treated with a modified FOLFOX
(biweekly oxaliplatin plus 5-FU and folinic acid) regimen. Median survival time in patients with low ERCC1 levels was significantly
longer than in those with high levels (15.8 vs 6.2 months; Po0.0001). Patients with high TS levels had longer survival than those with
low levels (12.2 vs 10.1 months; P¼0.01). Forty-eight patients with low ERCC1 and high TS levels had a median survival of 16.1
months (Po0.0001). The hazard ratio for patients with high ERCC1 expression was 9.4 (Po0.0001). In patients with high mRNA
levels of ERCC1, alternative chemotherapy regimens should be considered.
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Gastric cancer currently ranks the third among most common
cancers and will remain a significant cancer burden in China
during the next decade. In 2005, there were approximately 400000
new cases and 300000 deaths from gastric cancer (Yang, 2006).
There is currently no established standard regimen for advanced
gastric cancer; however, biweekly oxaliplatin plus 5-fluorouracil
(5-FU) and folinic acid (FOLFOX) was well tolerated and yielded
median survival times of 9.6–11.4 months in five phase II studies
(Louvet et al, 2002; Al-Batran et al, 2004; Chao et al, 2004; De Vita
et al, 2005; Lordick et al, 2005). Considerable published evidence
suggests that interindividual variation in response to 5-FU results
from variations in the thymidylate synthase (TS) mRNA expres-
sion levels of the tumour (Longley et al, 2003). A sensitive
quantitative polymerase chain reaction (QPCR) permits the
detection of mRNA in small quantities that could not be detected
by conventional methods used to detect proteins. TS mRNA levels
in frozen endoscopic biopsies were inversely related to response
and survival in 65 gastric cancer patients receiving neoadjuvant
5-FU plus cisplatin; median survival was 43 months for those with
low TS levels and 6 months for those with high levels (Lenz et al,
1996). However, some tumours expressing relatively high levels of
TS mRNA were surprisingly sensitive to 5-FU plus cisplatin
(Lenz et al, 1996; Metzger et al, 1998). Intriguingly, it has recently
been reported that gastric cancer cells that were rendered resistant
to oxaliplatin exhibited significantly decreased TS levels, which
resulted in enhanced susceptibility to 5-FU cytotoxicity.
In addition, host cell reactivation assay revealed enhanced
DNA repair of oxaliplatin damage in the resistant cells
(Chen et al, 2007).
Cytotoxicity from cisplatin and other platinum-containing
drugs, such as oxaliplatin, results from the formation of platinum
DNA adducts (Schellens et al, 1996; van de Vaart et al, 2000). One
determinant of the level of platinum DNA adducts in the tissue of
patients treated with platinum-containing drugs is the rate of DNA
repair. Individuals vary considerably in their capacity to remove
DNA adducts, and tumour cell lines demonstrating in vitro
resistance to cisplatin rapidly clear DNA adducts from the cells
(Bosken et al, 2002). Nucleotide excision repair (NER) is the major
pathway for repairing platinum-induced DNA damage. A series of
proteins act to recognise base damage, unwind DNA, remove the
damaged single-stranded fragment and synthesise a correct strand
in its place (de Laat et al, 1999; Rosell et al, 2007). Excision repair
cross-complementing 1 (ERCC1) is a key enzyme in the NER
pathway. ERCC1 and TS mRNA levels were examined in 38 of the
65 gastric cancer patients (Lenz et al, 1996), for whom sufficient
cDNA was available. Median survival for patients with low ERCC1
mRNA levels was not reached, while it was 5.4 months for those
with high levels (P¼0.034). The differences in median survival
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saccording to TS mRNA levels were not significant (Metzger et al,
1998).
To further clarify the prognostic value of TS and ERCC1 mRNA
expression, we examined by QPCR 76 formalin-fixed paraffin-
embedded tumour samples from FOLFOX-treated advanced
gastric cancer patients and correlated the results with survival.
PATIENTS AND METHODS
Patients
Patients with histologically proven locally advanced or metastatic
gastric cancer and Eastern Cooperative Oncology Group (ECOG)
performance status (PS) p2 were included in the study. All
patients received a modified FOLFOX regimen chemotherapy after
resection of primary tumours, as follows: oxaliplatin 85mgm
 2 on
day 1, plus folinic acid 200mgm
 2 as a 2h infusion followed by
bolus 5-FU 300mgm
 2 and a 22h infusion of 5-FU 600mgm
 2 on
days 1 and 2, every two weeks. Survival was calculated from the
date of diagnosis to the date of last follow-up or death from any
cause. All patients gave their signed informed consent, and the
study was approved by the institutional ethics review boards.
Total RNA extraction from formalin-fixed paraffin-
embedded tissue
Seven 7-mm sections were prepared from primary tumour blocks
that contained at least 80% tumour cells and directly transferred
into a microcentrifuge tube. RNA was extracted according to a
previously described method with minor modifications (Specht
et al, 2001). Briefly, paraffin was removed by extracting three times
with 1ml xylene for 10min incubation at 501C followed by
rehydration through subsequent washes with 100, 90 and 70%
ethanol diluted in RNase-free water. The tissue was collected by
centrifugation and resuspended in 200ml RNA lysis buffer
containing 10mM Tris-HCL, 0.1mM EDTA, 2% SDS and
500mgml
 1 proteinase K and incubated at 601C for 16h. RNA
was purified by phenol and chloroform extractions followed by
precipitation with isopropanol in the presence of sodium acetate
and at  201C. The RNA pellet was washed in 70% ethanol and
resuspended in 20ml of RNase-free water.
QPCR assessment of TS and ERCC1 expression
cDNA was generated with a blend of random hexamers and oligo-
dT 1:1 (ABgene, Surrey, UK) and the target cDNA sequences were
amplified by quantitative PCR in a fluorescent temperature cycler
(Mx 3000P Real Time PCR System, Stratagene). Briefly, total RNA
1mg was used for each RT reaction. The 20ml PCR reaction mixture
contained 1  primers and probe mixture (Applied Biosystems,
Foster city, CA, USA. Assay IDs: Hs00157415_m1 (ERCC1);
Hs00426591_m1 (TS); Hs99999903_m1 (b-actin)), 1  Absolute
QPCR Mix (ABgene). The PCR conditions were 501C for 2min,
951C for 15min, followed by 45 cycles at 951C for 15s and 601C for
1min. Relative gene expression quantifications were calculated
according to the comparative Ct method using b-actin as an
endogenous control and commercial human total RNA (BD
Clontech, CA, USA) as calibrators. Final results were determined
by the formula 2
 DDCt (Livak and Schmittgen, 2001) and were
analysed with the Stratagene analysis software.
Statistical analysis
The Mann–Whitney U-test was used to test significant association
between gene expression levels and dichotomous variables. The
Spearman’s rho method was used to correlate expression levels of
TS and ERCC1. The maximal w
2 method of Miller and Siegmund
(Miller and Siegmund, 1982) and Halpern (Halpern, 1982) was
adapted to determine which cutoff value best dichotomised
patients into low- and high-expression TS and ERCC1 subgroups;
the Tree method (LeBlanc and Crowley, 1992) was then applied to
optimise these cutoff values. The final cutoff values were
confirmed by recursive partitioning and amalgamation using
S-Plus software, version 6.1 (Statistical Sciences, Seattle, WA,
USA). Survival curves were obtained by the Kaplan–Meier
method. Comparisons were made with the log-rank test and
1000 bootstrap-like simulations were performed to get the
corrected P-values of the log-rank test. A univariate Cox model
with overall survival as the dependent variable was constructed
and categorised with gene expression levels as independent
variables, and the genes that were significant in the univariate
analysis were included in a multivariate Cox proportional hazards
model for survival. All statistical analyses were carried out at a
5% level of significance and with a power of 80%, using the
Statistical Package for the Social Sciences, version 13 (SPSS Inc,
Chicago, IL, USA).
RESULTS
Patient characteristics
A total of 76 gastric adenocarcinoma patients were included in the
study. The median age was 57; 56 patients were male and the
majority of patients had PS 0–1. Twenty-one patients (27.6%) had
stage IIIA, 16 (21.1%) had stage IIIB and 39 (51.3%) had stage IV
disease at the time of diagnosis. Patient characteristics are
summarised in Table 1.
Table 1 Clinical factors associated with overall survival
Patients
Characteristics No. Percentage
MST
(Months)
P Log-rank
test
Age, years (median: 57; range: 30–80)
o57 36 47.4 15.7 0.943
X57 40 52.6 10.7
Sex
Male 56 73.7 11.5 0.780
Female 20 26.3 11.7
ECOG PS
0–1 62 81.6 11.8 0.020
2 14 18.4 8.1
Initial staging
III 37 48.7 19.2 o 0.001
IV 39 51.3 9.6
Grading
G2 20 26.3 10.7 0.972
G3 56 73.7 11.8
Site of tumour
Proximal stomach 28 36.8 9.8 0.45
Distal stomach 42 55.3 12.2
Whole stomach 6 7.9 11.3
No.of sites involved
a
0–1 49 64.5 16.9 0.004
X2 27 35.5 7.6
Abbreviation: MST: median survival time.
aSites involved: lymph nodes, liver, pancreas,
peritoneum, lung, pleura.
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ERCC1 and TS levels were detected in all tumours, with median
gene expression relative to housekeeping b-actin for ERCC1 of
0.039 (range 0.001–5.23, 95% confidence interval (CI): 0.26–0.83)
and for TS of 8.83 (range 0.72–78.79, 95% CI: 8.03–12.34). Using a
cutoff value of 0.47, 61 patients (80.3%) had low ERCC1 expression
levels and 15 (19.7%) patients had high levels. Using a cutoff value
of 6.06, 55 (72.4%) patients had low TS expression levels and 21
(27.6%) had high levels. There was no significant association
between ERCC1 and TS levels (r¼ –0.1, P¼0.39). ERCC1 mRNA
expression levels were lower in patients with PS 0–1 (median
value: 0.017) than in those with PS 2 (median value: 0.099)
(P¼0.03). Distal gastric cancer was present in 62.3% of patients
with low ERCC1 levels and proximal gastric cancer was present in
53.3% of patients with high ERCC1 levels (P¼0.02). No significant
association was detected between ERCC1 or TS mRNA expression
and other clinical parameters.
Survival
Median survival time for all patients was 11.5 months (95% CI:
8.4–14.6 months). A significant association was observed between
survival and PS (P¼0.02), tumour stage (Po0.001) and number of
sites involved (P¼0.004). No other association between clinical
characteristics and survival was found (Table 1).
A significant association was also observed between survival and
gene expression levels. Median survival for patients with low
ERCC1 expression levels was 15.8 months (95% CI: 10.2–21.5
months) compared with 6.2 months (95% CI: 4.6–7.9 months) for
those with high levels (Po0.0001) (Table 2, Figure 1). Median
survival for patients with high TS expression levels was 12.2
months (95% CI: 3.7–16.4 months) compared to 10.1 months (95%
CI: 5.4–18.9 months) for those with high levels (P¼0.01) (Table 2).
Among the 55 patients with high TS expression levels, 48
patients with low ERCC1 levels had a median survival of 16.1
months (95%CI: 7.8–24.4) compared to 6.9 months (95% CI:
5.2–8.6) for the seven patients with high ERCC1 levels (Po0.0001)
(Figure 2A). Among the 21 patients with low TS expression levels,
13 patients with low ERCC1 levels had a median survival of 15.1
months (95% CI: 9.2–21.1) compared to 5 months (95% CI: 4–6.1)
for the 8 patients with high ERCC1 levels (P¼0.001) (Figure 2B).
The multivariate analysis identified ERCC1 mRNA expression
levels (hazard ratio (HR), 9.4; Po0.0001) and number of sites
involved (HR, 1.9; P¼0.03) as independent markers for survival
(Table 3).
DISCUSSION
In this first QPCR analysis of ERCC1 and TS mRNA expression in
formalin-fixed paraffin-embedded tumour tissue in advanced
gastric cancer, we have found that ERCC1 – but not TS – mRNA
expression is associated with survival in patients receiving a
modified FOLFOX regimen. These findings are along the same
lines as the seminal study by Metzger et al (1998) where ERCC1
and TS mRNA levels were quantified in frozen tumour tissue from
gastric cancer patients receiving 5-FU plus cisplatin. Since the time
of writing the present report, another study in paraffin-embedded
tumour tissue has confirmed the role of ERCC1 mRNA expression
in a heterogeneous cohort of gastric cancer patients – 69 treated
Table 2 ERCC1 and TS mRNA expression and survival in advanced
gastric cancer patients
Factors No. of patients MST (Months) (95% CI) P
a
ERCC1 mRNA
Low p0.47 61 15.8 (10.2–21.5) o0.0001
High 40.47 15 6.2 (4.6–7.9)
TS mRNA
Low p6.06 21 10.1 (5.4–18.9) 0.01
High 46.06 55 12.2 (3.7–16.4)
aAdjusted P-value based on log-rank statistics after 1000 bootstrap simulations.
1.0
0.8
0.6
0.4
0.2
P
r
o
b
a
b
i
l
i
t
y
0.0
0.00 10.00 20.00 30.00
Months
High ERCC1
Low ERCC1
40.00 50.00 60.00
Figure 1 Kaplan–Meier estimates of overall survival by ERCC1 mRNA
expression levels (N¼76; low ERCC1: 61; high ERCC1: 15).
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Figure 2 Kaplan–Meier estimates of overall survival according to ERCC1
mRNA expression in patients with high TS mRNA expression (A)( N¼55;
high TS and low ERCC1: 48; high TS and high ERCC1: 7) and in patients with
low TS expression (B)( N¼21; low TS and low ERCC1: 13; low TS and high
ERCC1: 8).
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swith S-1, 23 with 5-FU and 43 with cisplatin plus either irinotecan
or S-1. In the multivariate analysis of all 140 patients, ERCC1
emerged as an independent prognostic marker of survival (HR, 2.4;
Po0.001); however, TS mRNA expression was not significant (HR,
0.3) (Matsubara et al, 2008). A study assessing ERCC1 and TS by
immunostaining in 64 advanced gastric cancer patients treated
with FOLFOX also showed significant differences according to
ERCC1 expression. Median survival for patients with negative
ERCC1 was 12.8 months, while it was 8.4 months for those with
positive ERCC1 (P¼0.03). The multivariate analysis revealed a
significant impact of ERCC1 expression on survival (HR, 1.9;
P¼0.04) (Kwon et al, 2007). However, TS expression was not
found to be related to response or survival (Kwon et al, 2007),
which concurred with the findings of a previous study (Choi et al,
2001). However, in the present study, using QPCR, the differences
are much more striking (15.8 vs 6.2 months; Po0.0001), with a HR
of 9.4. The determination of relative gene expression through
QPCR is currently considered to be a more sensitive and more
quantitative methodology than immunostaining. Several studies
have found no correlation between mRNA and protein levels of
ERCC1 (Britten et al, 2000; Niedernhofer et al, 2007). When ERCC1
expression at the mRNA and protein levels was assessed by
northern and western blotting, respectively, in a panel of cervical
carcinoma cell lines, there was a significant correlation between
ERCC1 mRNA – but not ERCC1 protein – levels and cisplatin
resistance (Britten et al, 2000). In stage IV, non-small-cell lung
cancer patients treated with cisplatin-based chemotherapy, ERCC1
protein expression did not predict response (Wachters et al, 2005),
whereas ERCC1 mRNA expression was significantly associated
with response (Cobo et al, 2007). Previous studies have tested
ERCC1 mRNA expression in paraffin-embedded tumour samples
in advanced colorectal cancer patients treated with 5-FU plus
oxaliplatin (Shirota et al, 2001) and in non-small-cell lung cancer
patients treated with gemcitabine plus cisplatin (Lord et al, 2002);
both studies found a significant association between ERCC1
expression and survival. Cisplatin resistance is multifactorial, also
involving the copper transporter ATP7A (Chen et al, 2007) and a
45-gene expression signature was a predictor of cisplatin
sensitivity with 83% accuracy (Hsu et al, 2007). Interestingly, this
gene signature includes ERCC1 and other DNA repair genes.
It is not clear, either in the Metzger study (Metzger et al, 1998)
or in the present one, whether ERCC1 is a prognostic or a
predictive marker. Interestingly, in the present study, ERCC1
mRNA levels were lower in patients with good PS, which has
also been found in non-small-cell lung cancer patients (Cobo et al,
2007).
The role of TS in predicting chemosensitivity remains con-
troversial (Choi et al, 2001; Kwon et al, 2007; Matsubara et al,
2008). Although a meta-analysis reported that colorectal cancer
patients with higher TS levels had poorer overall survival than
those with lower levels (Popat et al, 2004), this predictive value was
not confirmed in a prospective study (Smorenburg et al, 2006). In
the present study, patients with higher TS levels had longer
survival than those with lower levels, especially in patients with
lower ERCC1 levels. Low levels of TS have been observed in
oxaliplatin-resistant gastric cancer cell lines (Chen et al, 2007),
providing a plausible potential explanation of why a meaningful
number of patients with low ERCC1 and high TS levels had the
longest survival in the present study (Figure 2).
Irinotecan and taxane-based regimens have been used in the
treatment of advanced gastric cancer patients, with survival times
similar to those attained with FOLFOX (Moehler et al, 2005; Oh
et al, 2007; Takayama et al, 2007). However, the short survival
attained in FOLFOX-treated patients with positive protein ERCC1
(HR, 1.91) (Kwon et al, 2007) or overexpression of ERCC1 mRNA
(HR, 9.4) suggests that irinotecan or taxane-based regimens could
be the better alternative for these patients. A randomised
customised trial is warranted in this setting.
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